Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Infect Prev Pract ; 5(4): 100316, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-38028364

RESUMEN

Background: This report details how one large medical center in the Metropolitan New York area re-purposed a drive-through COVID-19 vaccination structure to handle a surge in Mpox cases in July 2022.Methods/Results: Simultaneous to on-going COVID -19 vaccination and testing, Mpox vaccination was rolled out in the same drive through structure. More than 1,820 Jynneos (Smallpox and Monkeypox Vaccine, Live, Non-replicating) vaccine dosages were delivered subcutaneously and then intradermally to 1,123 individuals through the open window of their vehicles, averaging 8-10 patients an hour. Five vaccine recipients suffered Mpox rash; there was no exposure among healthcare providers. Conclusion: Drive-through vaccination is an efficient model to be redeployed for future unexpected vaccine initiatives.

2.
Transplant Cell Ther ; 27(5): 438.e1-438.e6, 2021 05.
Artículo en Inglés | MEDLINE | ID: mdl-33728417

RESUMEN

An evidence-based triage plan for cellular therapy distribution is critical in the face of emerging constraints on healthcare resources. We evaluated the impact of treatment delays related to COVID-19 on patients scheduled to undergo hematopoietic cell transplantation (HCT) or chimeric antigen receptor T-cell (CAR-T) therapy at our center. Data were collected in real time between March 19 and May 11, 2020, for patients who were delayed to cellular therapy. We evaluated the proportion of delayed patients who ultimately received cellular therapy, reasons for not proceeding to cellular therapy, and changes in disease and health status during delay. A total of 85 patients were delayed, including 42 patients planned for autologous HCT, 36 patients planned for allogeneic HCT, and 7 patients planned for CAR-T therapy. Fifty-six of these patients (66%) since received planned therapy. Five patients died during the delay. The most common reason for not proceeding to autologous HCT was good disease control in patients with plasma cell dyscrasias (75%). The most common reason for not proceeding to allogeneic HCT was progression of disease (42%). All patients with acute leukemia who progressed had measurable residual disease (MRD) at the time of delay, whereas no patient without MRD at the time of delay progressed. Six patients (86%) ultimately received CAR-T therapy, including 3 patients who progressed during the delay. For patients with high-risk disease such as acute leukemia, and particularly those with MRD at the time of planned HCT, treatment delay can result in devastating outcomes and should be avoided if at all possible.


Asunto(s)
COVID-19 , Trasplante de Células Madre Hematopoyéticas , Inmunoterapia Adoptiva , Pandemias , SARS-CoV-2 , Tiempo de Tratamiento , Adulto , Anciano , Aloinjertos , Amiloidosis/terapia , Anemia Aplásica/terapia , COVID-19/complicaciones , COVID-19/epidemiología , COVID-19/transmisión , Defensa Civil , Infección Hospitalaria/epidemiología , Infección Hospitalaria/prevención & control , Progresión de la Enfermedad , Práctica Clínica Basada en la Evidencia/organización & administración , Femenino , Trasplante de Células Madre Hematopoyéticas/estadística & datos numéricos , Humanos , Control de Infecciones/métodos , Transmisión de Enfermedad Infecciosa de Profesional a Paciente , Leucemia/mortalidad , Leucemia/patología , Leucemia/terapia , Masculino , Persona de Mediana Edad , Enfermedades Mielodisplásicas-Mieloproliferativas/mortalidad , Enfermedades Mielodisplásicas-Mieloproliferativas/terapia , Neoplasia Residual , Neoplasias/mortalidad , Neoplasias/terapia , Ciudad de Nueva York/epidemiología , Asignación de Recursos , Tiempo de Tratamiento/estadística & datos numéricos , Trasplante Autólogo , Triaje/organización & administración , Adulto Joven
5.
J Nutr Elder ; 28(1): 81-95, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19234997

RESUMEN

Herbal supplements (HS) are used by older persons and are often perceived as safe, although there is limited research that examines why this perception exists. A questionnaire was developed and pilot tested to investigate the use and perceived safety of HS among a convenience sample of 112 adults aged 60 to 92 in southeast Idaho. Fifty-five percent of the participants (n = 62) reported using HS in the past. Ninety-five percent (n = 59) of those using HS and 75% (n = 37) of nonusers reported they believed most or some HS were safe. Perception of herbal supplement safety was greatly influenced by family and friends, and HS users had a greater perception of safety than nonusers (p < or = .001). The top reasons for perceived safety given by HS users were that HS: (1) can be purchased without a prescription, (2) can be purchased in many locations, and (3) are natural.


Asunto(s)
Seguridad de Productos para el Consumidor , Suplementos Dietéticos/estadística & datos numéricos , Medicamentos sin Prescripción/administración & dosificación , Preparaciones de Plantas/administración & dosificación , Anciano , Anciano de 80 o más Años , Suplementos Dietéticos/efectos adversos , Femenino , Conductas Relacionadas con la Salud , Interacciones de Hierba-Droga , Humanos , Idaho , Masculino , Persona de Mediana Edad , Medicamentos sin Prescripción/efectos adversos , Satisfacción del Paciente , Proyectos Piloto , Preparaciones de Plantas/efectos adversos , Encuestas y Cuestionarios
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA